Docket Number:12A-1050902
Inventor:Patrick CH Hsieh, Desy, S. Lee
IP Status:Pending
Abstract:
The pluripotent stem cells-derived cardiomyocytes need to be in a mature state in advance to be used for disease modeling, drug screening, or cell-based therapies. Our finding showed that the coculture system with endothelial cells or the delivery of microRNA cocktail (miR-125b, miR-199a, miR-221, and miR-222) could be used to enhance the structural and functional maturation of these pluripotent stem cells-derived cardiomyocytes.
Fields of Application:
- Therapeutic use (cell therapy)
- Drug development (drug screening or cardiac toxicity test)
- Research use (disease modeling)
Advantages when compared to the existing technologies:
- based on real physiological mechanisms, avoiding unexpected side-effects.
- miRNAs have the potential to regulate many targets and complex pathways and are still more selective than many small molecule agents.
- miRNAs are easy to manipulate ex vivo
- persist for at least two months after a single miR-combo delivery
Contact Person:
對本技術有興趣,請於本處網頁廠商選項下(廠商需求與諮詢)網頁填寫資料,承辦人將跟您聯絡。
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Apply for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office, and the undertaker will contact you.
